TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS WITH ERYTHROPOIETIN - LONG-TERM EFFECTS ON EXERCISE CAPACITY

被引:0
|
作者
BARANY, P [1 ]
FREYSCHUSS, U [1 ]
PETTERSSON, E [1 ]
BERGSTROM, J [1 ]
机构
[1] HUDDINGE UNIV HOSP, DEPT CLIN PHYSIOL, S-14186 HUDDINGE, SWEDEN
关键词
ANEMIA; ERYTHROPOIETIN; EXERCISE; HEMODIALYSIS; UREMIA;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1. The effects of correcting anaemia on exercise capacity were evaluated in 21 haemodialysis patients (aged 39 +/- 12 years) before starting treatment with recombinant human erythropoietin (Hb concentration, 73 +/- 10 g/l; total Hb, 59 +/- 12% of expected), after correction of the anaemia to a Hb concentration of 108 +/- 7 g/l and a total Hb 82 +/- 10% of expected, and in 13 of the patients after 12 months on maintenance recombinant human erythropoietin treatment (Hb concentration 104 +/- 14 g/l, total Hb 79 +/- 17% of expected). Fifteen healthy subjects (aged 41 +/- 9 years), who took no regular exercise, constituted the control group. Maximal exercise capacity was determined on a bicycle ergometer. Oxygen uptake, respiratory quotient, blood lactate concentration, heart rate and blood pressure were measured at rest and at maximal workload. 2. After 6 +/- 3 months on recombinant human erythropoietin, maximal exercise capacity increased from 108 +/- 27 W to 130 +/- 36 W (P<0.001) and the maximal oxygen uptake increased from 1.24 +/- 0.39 litres/min to 1.50 +/- 0.45 litres/min (P<0.001). No significant changes in respiratory quotient (1.16 +/- 0.13 versus 1.18 +/- 0.13) and blood lactate concentration (4.0 +/- 1.8 versus 3.6 +/- 1.1 mmol/1) at maximal workload were observed, but the blood lactate concentration in the patients was significantly lower than that in the control subjects (6.7 +/- 2.3 mmol/l, P<0.01). After the correction of anaemia, the aerobic power was still 38% lower in the patients than in the control subjects and 17% lower than the reference values. 3. After 12 months on maintenance recombinant human erythropoietin treatment (17 +/- 3 months from the start of the study), no further significant changes were observed in maximal exercise capacity (before start, 112 +/- 31 W, 6 +/- 3 months, 134 +/- 42 W, 17 +/- 3 months, 134 +/- 50 W), maximal oxygen uptake (before start, 1.33 +/- 0.45 litres/min; 6 +/- 3 months, 1.59 +/- 0.54 litres/min; 17 +/- 3 months, 1.75 +/- 0.78 litres/min) or blood lactate concentration (before start, 4.4 +/- 1.9 mmol/l; 6 +/- 3 months, 4.0 +/- 1.0 mmol/l; 17 +/- 3 months, 4.7 +/- 2.0 mmol/l). 4. Thus, in haemodialysis patients the improvement in maximal aerobic power after the correction of anaemia persists without marked changes during long-term treatment with recombinant human erythropoietin. We did not observe any effects on exercise capacity that could be attributed to a spontaneous increase in physical activity after treatment of anaemia.
引用
收藏
页码:441 / 447
页数:7
相关论文
共 50 条
  • [21] LONG-TERM EFFECTS ON LYMPHOCYTOTOXIC ANTIBODIES AND IMMUNE REACTIVITY IN HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BARANY, P
    FEHRMAN, I
    GODOY, C
    CLINICAL NEPHROLOGY, 1992, 37 (02) : 90 - 96
  • [22] EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) FOR CORRECTION OF ANEMIA IN PATIENTS ON LONG-TERM HEMODIALYSIS (HD)
    WEISS, L
    WENTZEL, T
    FRISENETTEFICH, C
    HOFFSTEDT, E
    LINDBERGER, K
    MASCHER, G
    NIELSEN, F
    PRUTZ, K
    WESSEN, P
    KIDNEY INTERNATIONAL, 1992, 41 (02) : 506 - 507
  • [23] LONG-TERM MYOCARDIAL EFFECTS OF CORRECTION OF ANEMIA WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN AGED PATIENTS ON HEMODIALYSIS
    MARTINEZVEA, A
    BARDAJI, A
    GARCIA, C
    RIDAO, C
    RICHART, C
    OLIVER, JA
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (04) : 353 - 357
  • [24] EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) ON HEMODYNAMIC AND METABOLIC RESPONSE DURING EXERCISE IN HEMODIALYSIS-PATIENTS WITH ANEMIA
    ITOH, H
    YANAGISAWA, E
    IKEDA, C
    NAKAMURA, M
    HATOGAI, F
    SHIMADA, T
    IWADARE, M
    CIRCULATION, 1992, 86 (04) : 400 - 400
  • [25] CARDIAC EFFECTS OF LONG-TERM TREATMENT OF RENAL ANEMIA BY RECOMBINANT ERYTHROPOIETIN
    GRUTZMACHER, P
    BERGMANN, M
    LOWFRIEDRICH, I
    RAUBER, K
    BAUM, R
    SCHOEPPE, W
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1990, 19 (05) : 192 - 198
  • [26] Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
    Oh, Jieun
    Joo, Kwon-Wook
    Chin, Ho-Jun
    Chae, Dong-Wan
    Kim, Sung-Gyun
    Kim, Soo Jin
    Chung, Wookyung
    Kim, Sejoong
    Huh, Wooseong
    Oh, Ha Young
    Choi, Bum Soon
    Yang, Chul-Woo
    Kim, Suhnggwon
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (01) : 76 - 83
  • [27] IRON OVERLOAD AND MOBILIZATION IN LONG-TERM HEMODIALYSIS-PATIENTS
    HAKIM, RM
    STIVELMAN, JC
    SCHULMAN, G
    FOSBURG, M
    WOLFE, L
    IMBER, MJ
    LAZARUS, JM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1987, 10 (04) : 293 - 299
  • [28] PATHOBIOLOGY AND FUNCTIONAL STATUS OF LONG-TERM HEMODIALYSIS-PATIENTS
    IFUDU, O
    BREZSNYAK, WF
    REYDEL, C
    MCCLENDON, E
    SURGRUE, T
    DIRIENZO, R
    AVRAM, MM
    FRIEDMAN, EA
    AMERICAN JOURNAL OF NEPHROLOGY, 1995, 15 (05) : 379 - 385
  • [29] HEPATIC GRANULOMATA IN LONG-TERM HEMODIALYSIS-PATIENTS WITH HYPERALUMINUMEMIA
    KURUMAYA, H
    KONO, N
    NAKANUMA, Y
    TOMODA, F
    TAKAZAKURA, E
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 1989, 113 (10) : 1132 - 1134
  • [30] SILICONE STORAGE DISEASE IN LONG-TERM HEMODIALYSIS-PATIENTS
    BOMMER, J
    WALDHERR, R
    RITZ, E
    CONTRIBUTIONS TO NEPHROLOGY, 1983, 36 : 115 - 126